FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160393522> ?p ?o ?g. }

• W3160393522 endingPage "102" @default.
• W3160393522 startingPage "90" @default.
• W3160393522 abstract "Effective treatment regimens for triple-negative breast cancer (TNBC) are relatively scarce due to a lack of specific therapeutic targets. Epidermal growth factor receptor (EGFR) signaling is highly active in TNBC and is associated with poor prognosis. Most EGFR antagonists, which significantly improve outcome in lung and colon cancer, have shown limited clinical effects in breast cancer. However, limiting EGFR expression in TNBC is a potential strategy for improving the clinical efficacy of EGFR antagonists. Here, we found that the gamma-aminobutyric acid type A receptor π subunit (GABRP), as a membrane protein enriched in TNBC stem cells, interacted with EGFR and significantly sustained its expression, resulting in stemness maintenance and chemotherapy resistance. Silencing GABRP induced down-regulation of EGFR signaling, which hindered cell stemness and enhanced sensitivity to chemotherapies, including paclitaxel, doxorubicin, and cisplatin. We also identified that retigabine, an FDA-approved drug for adjunctive treatment of seizures, increased the sensitivity of EGFR to gefitinib in gefitinib-resistant cells. Our findings show that GABRP can sustain the stemness of TNBC via modulating EGFR expression, suggesting that GABRP may be a potential therapeutic target that can address EGFR inhibitor resistance in TNBC." @default.
• W3160393522 created "2021-05-24" @default.
• W3160393522 creator A5035296788 @default.
• W3160393522 creator A5035876132 @default.
• W3160393522 creator A5045070510 @default.
• W3160393522 creator A5046519734 @default.
• W3160393522 creator A5049235701 @default.
• W3160393522 creator A5052493382 @default.
• W3160393522 creator A5054535728 @default.
• W3160393522 creator A5060860709 @default.
• W3160393522 creator A5064554241 @default.
• W3160393522 creator A5068593113 @default.
• W3160393522 creator A5081052692 @default.
• W3160393522 creator A5089189597 @default.
• W3160393522 date "2021-08-01" @default.
• W3160393522 modified "2023-10-18" @default.
• W3160393522 title "GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling" @default.
• W3160393522 cites W1788858634 @default.
• W3160393522 cites W1915010695 @default.
• W3160393522 cites W1919584830 @default.
• W3160393522 cites W1968885065 @default.
• W3160393522 cites W1976887222 @default.
• W3160393522 cites W1987113772 @default.
• W3160393522 cites W1990148464 @default.
• W3160393522 cites W1993695011 @default.
• W3160393522 cites W1999251458 @default.
• W3160393522 cites W2006168411 @default.
• W3160393522 cites W2014332691 @default.
• W3160393522 cites W2016498201 @default.
• W3160393522 cites W2020555298 @default.
• W3160393522 cites W2032323336 @default.
• W3160393522 cites W2035159186 @default.
• W3160393522 cites W2037690883 @default.
• W3160393522 cites W2048203596 @default.
• W3160393522 cites W2051920240 @default.
• W3160393522 cites W2052988773 @default.
• W3160393522 cites W2053740346 @default.
• W3160393522 cites W2055498399 @default.
• W3160393522 cites W2066446030 @default.
• W3160393522 cites W2069663935 @default.
• W3160393522 cites W2082239705 @default.
• W3160393522 cites W2092714850 @default.
• W3160393522 cites W2096283457 @default.
• W3160393522 cites W2098920248 @default.
• W3160393522 cites W2102085111 @default.
• W3160393522 cites W2106001183 @default.
• W3160393522 cites W2108830619 @default.
• W3160393522 cites W2113711412 @default.
• W3160393522 cites W2114909824 @default.
• W3160393522 cites W2119748249 @default.
• W3160393522 cites W2120490763 @default.
• W3160393522 cites W2120661754 @default.
• W3160393522 cites W2121104475 @default.
• W3160393522 cites W2125797780 @default.
• W3160393522 cites W2127457810 @default.
• W3160393522 cites W2138474420 @default.
• W3160393522 cites W2151730005 @default.
• W3160393522 cites W2153490235 @default.
• W3160393522 cites W2154149901 @default.
• W3160393522 cites W2157637017 @default.
• W3160393522 cites W2159640574 @default.
• W3160393522 cites W2293126224 @default.
• W3160393522 cites W2299045691 @default.
• W3160393522 cites W2402636472 @default.
• W3160393522 cites W2585007332 @default.
• W3160393522 cites W2594614544 @default.
• W3160393522 cites W2616011222 @default.
• W3160393522 cites W2736730167 @default.
• W3160393522 cites W2741737927 @default.
• W3160393522 cites W2763136348 @default.
• W3160393522 cites W2765899161 @default.
• W3160393522 cites W2766249538 @default.
• W3160393522 cites W2770828094 @default.
• W3160393522 cites W2803370004 @default.
• W3160393522 cites W2805664667 @default.
• W3160393522 cites W2888150662 @default.
• W3160393522 cites W2889373434 @default.
• W3160393522 cites W2906744990 @default.
• W3160393522 cites W2919144854 @default.
• W3160393522 cites W2937830908 @default.
• W3160393522 cites W2955001509 @default.
• W3160393522 cites W2967965881 @default.
• W3160393522 cites W2991955247 @default.
• W3160393522 cites W2999417355 @default.
• W3160393522 cites W3000285141 @default.
• W3160393522 cites W3000606414 @default.
• W3160393522 cites W3022903836 @default.
• W3160393522 cites W3025384039 @default.
• W3160393522 cites W3081224187 @default.
• W3160393522 cites W3087148108 @default.
• W3160393522 cites W4211005384 @default.
• W3160393522 doi "https://doi.org/10.1016/j.canlet.2021.04.028" @default.
• W3160393522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34023418" @default.
• W3160393522 hasPublicationYear "2021" @default.
• W3160393522 type Work @default.
• W3160393522 sameAs 3160393522 @default.
• W3160393522 citedByCount "12" @default.
• W3160393522 countsByYear W31603935222021 @default.

• next